Popular Articles

SPECT MPI With Cardiolite(R) Used In BARI 2D Study To Evaluate Type 2 Diabetes And Coronary Artery Disease Treatment Strategies
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announced today that the company"s leading imaging agent, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), was used in a recently completed five-year study examining appropriate treatment regimens for patients with type 2 diabetes and coronary artery disease. The results of this study, known as The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D), will be presented by the University of Pittsburgh Graduate School of Public Health at a special symposium on Sunday, June 7, 2009, from 4:15 p.m. - 5:15 p.m. (CT) at the American Diabetes Association 69th Scientific Sessions in New Orleans.

Top Notch Topknot: Times Journalist Sathnam Sanghera Wins Mind Book Of The Year Award 2009
Mental health charity Mind has announced that Times journalist Sathnam Sanghera has won this year"s Mind Book of the Year Award for "The Boy with the Topknot: a memoir of love, secrets and lies in Wolverhampton" (1). The memoir is about growing up in Wolverhampton and retrospectively discovering at the age of 24 that both his father and sister had schizophrenia.
News of the day
Agencies And Health Departments Prepare For Swine Flu
Governments and drug companies are struggling with efforts to prepare for a possible resurgence of swine flu in the fall as well as questioning who should receive swine flu vaccines as they ramp up production.
Cardiovascular

Victorian Invention A Watchful Approach To Parkinson's

Victoria, Australia researchers have developed a wristwatch that continuously monitors the health status of people with Parkinson"s disease to help doctors manage their treatment, Victorian Minister for Innovation Gavin Jennings said today. The wristwatch, which is still at the prototype stage, was introduced onto the world market by Mr. Jennings at the 2009 BIO International Convention in Atlanta, USA. It is designed to assist doctors treating people with Parkinson"s disease by recording their symptoms throughout the day and in the longer term will assist researchers in the development of new drugs for the disease. "The Brumby Government is taking action to promote innovative projects in Victoria and this is an excellent example of how Victorian scientists are moving from basic research into developing products that will clearly benefit patients and their families," Mr. Jennings said. "The right dosage and correct timing of dosing has an enormous impact on the wellbeing of a person with Parkinson"s disease. Currently neurologists can only check dosage and timing by observing the patient during consultations, which may be at 6-8 week intervals. "What this clever device does is provide the physician with an objective measurement of how a patient"s symptoms have changed over time. It is the first of its kind and will provide physicians with information about the effectiveness of medications and guide them in adjusting the timing of medications." The wristwatch (patent pending) has been developed by a team led by Professor Mal Horne and Dr. Rob Griffiths at the Florey Neuroscience Institutes in Melbourne. Mr. Jennings said the device would assist in the development of drugs for Parkinson"s disease which was hampered by an inability to accurately assess whether the treatment is effective. The next stage of development for the wristwatch - to prepare it for commercial sale - is being funded by Melbourne"s Medical Research Commercialisation Fund. The MRCF is a collaborative venture fund established with support from the Victorian and NSW Governments. Dr. Chris Nave, Principal Executive of the MRCF, said the fund had invested an initial $490,000 in Global Kinetics Corporation, a spinout company from the Melbourne-based Florey Neuroscience Institutes to enable researchers to further refine the watch and complete pivotal clinical trials. "We are very pleased to be involved in taking this simple, yet effective, device to its next stage," said Mr. Nave. Parkinson"s disease is a degenerative disorder of the brain that often affects body movements and speech. About 80,000 people are living with Parkinson"s in Australia with one in five people with Parkinson"s diagnosed before the age of 50. In the USA, the disease affects up to two percent of the population and is the most common neurodegenerative movement disorder. Victorian Invention


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):